Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05896189 · ClinicalTrials.gov registry record · NA

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

A NA study of Breast Cancer and Cognitive Impairments, sponsored by NRG Oncology.

Recruiting
Registry status
NA
Development phase
386
Enrollment target
20
Study locations

NCT05896189: Recruiting NA study of Breast Cancer and Cognitive Impairments, sponsored by NRG Oncology.

NCT05896189 is a NA study of Breast Cancer and Cognitive Impairments that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 386 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05896189, a NA study of Breast Cancer and Cognitive Impairments, is actively recruiting participants, sponsored by NRG Oncology.

RECRUITING
Registry status
NA
Development phase
386 participants
Enrollment target
20
Study locations

Study Summary

This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.

Primary Outcome

FACT-Cog PCI scale score (Functional Assessment of Cancer Therapy-Cognitive Function-perceived cognitive impairment)

Interventions

  • BEHAVIORAL Arm 1: Computerized Cognitive Training-Global Stimulation Games
  • BEHAVIORAL Arm 2: Computerized Cognitive Training-Neuroplasticity Games

Study Locations (20)

Arizona

  • Arizona Center for Cancer Care - Gilbert - Gilbert
  • CTCA at Western Regional Medical Center - Goodyear
  • Arizona Center for Cancer Care-Peoria - Peoria
  • Cancer Center at Saint Joseph's - Phoenix
  • Arizona Center for Cancer Care - Biltmore - Phoenix
  • Arizona Center for Cancer Care - Phoenix - Phoenix
  • Mayo Clinic Hospital in Arizona - Phoenix
  • Arizona Center for Cancer Care - Osborn - Scottsdale
  • Arizona Center for Cancer Care - Scottsdale - Scottsdale
  • Arizona Center for Cancer Care-Surprise - Surprise
  • Arizona Center for Cancer Care - Tempe

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Anchorage Radiation Therapy Center - Anchorage
  • Alaska Breast Care and Surgery LLC - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage
  • Fairbanks Memorial Hospital - Fairbanks

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith

Trial Details

FieldValue
Enrollment Target 386 participants
Start Date 2024-04-12
Est. Completion 2027-11-30
Phase NA
NRG Oncology

64 total trials

What NCT05896189 shows while recruiting

NCT05896189 is an interventional study that assigns participants to a tested intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Arm 1: Computerized Cognitive Training-Global Stimulation Games is the first listed.

NCT05896189 names 20 study sites across 3 states, led by Arizona, Alaska, Arkansas.

Frequently Asked Questions

What is clinical trial NCT05896189 about?

NCT05896189 is a clinical study titled "Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors". This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.

What is the current status of trial NCT05896189?

This trial is currently recruiting. It is a NA study. The enrollment target is 386 participants. The study started on 2024-04-12. Estimated completion is 2027-11-30.

What conditions does trial NCT05896189 study?

This clinical trial studies the following conditions: Breast Cancer, Cognitive Impairments.

What interventions are being tested in trial NCT05896189?

The interventions under investigation include: Arm 1: Computerized Cognitive Training-Global Stimulation Games (BEHAVIORAL), Arm 2: Computerized Cognitive Training-Neuroplasticity Games (BEHAVIORAL).

Who is sponsoring clinical trial NCT05896189?

This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05896189 being conducted?

This trial has 20 study locations across Alaska, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05896189's enrollment target sits among peer trials

386 247th of 1224 higher than 977 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05645107 · 386 participants · Phase 3

    A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • NCT06686121 · 386 participants · Phase 3

    Improving Mobility After Revascularization in Peripheral Artery Disease

  • NCT03761108 · 387 participants · Phase 1

    Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

  • NCT05572632 · 387 participants · NA

    Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05896189, the US trial registry maintained by the National Library of Medicine. NCT05896189 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.